Why Did Forest Laboratories Buy Furiex Pharmaceuticals?

Forest Laboratories  (NYSE: FRX  ) has decided to get in on the recent M&A spree in health care with a $1.1 billion acquisition of Furiex Pharmaceuticals (UNKNOWN: FURX.DX  ) . That doesn't cover the total potential consideration, as Furiex shareholders could receive up to an additional $30 per share (or roughly $360 million) depending on the development of eluxadoline, a treatment for a form of irritable bowel syndrome (IBS-D), which Furiex anticipates submitting to the FDA for approval in the third quarter of 2014.

Forest Labs intends to defray some of the deal's costs by selling Furiex's royalty rights to drugs Nesina and Priligy for $415 million, although reportedly the company will retain royalty rights to Oseni and Kazano, both DPP-4 inhibitors for type 2 diabetes.

What makes this an even more interesting acquisition is that Actavis (NYSE: AGN  ) agreed to acquire Forest for $25 billion earlier this year, so it's an acquisition within an acquisition. Check out the video below for more thoughts and commentary on the acquisition, and particularly for the answer to the most critical question: Does this purchase even make sense?

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2934286, ~/Articles/ArticleHandler.aspx, 8/30/2015 4:02:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
FRX $0.00 Down +0.00 +0.00%
Forest Laboratorie… CAPS Rating: ****
FURX.DX $0.00 Down +0.00 +0.00%
Furiex Pharmaceuti… CAPS Rating: **
AGN $308.01 Down -3.99 -1.28%
Allergen PLC CAPS Rating: ****